Sangro, B., Bouattour, M., Park, J., Diaz, D. C., Erinjeri, J. P., Alves, G. V., Gu, S., Manikhas, A., Kuroda, H., Suksombooncharoen, T., Vo, T. H. T., Ostwal, V. S., Eastgate, M. A., Vaccaro, G. M., Griffin, R., Ali, S., Balaji, K., Chan, S. L. (2025). Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) + bevacizumab (B) + transarterial chemoembolization (TACE) and placebos + TACE: EMERALD-1 post hoc analysis.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.4_suppl.574